Cerevel Therapeutics Holdings Past Earnings Performance
Past criteria checks 0/6
Cerevel Therapeutics Holdings's earnings have been declining at an average annual rate of -15.9%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-15.9%
Earnings growth rate
120.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -64.2% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate
Jan 02
Cerevel overweight at Wells Fargo due to candidates with blockbuster potential
Sep 26Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering
Aug 12Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13
Aug 01Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded
Jul 08Cerevel Therapeutics: Pfizer's Neurology Spin-Off
Jul 14We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate
Jun 09Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?
Jan 29Cerevel Therapeutics (CERE) Investor Presentation - Slideshow
Nov 18Cerevel Therapeutics reports Q3 results
Nov 16Dosing underway in Cerevel Therapeutics' tavapadon trials for Parkinson’s disease
Oct 30Revenue & Expenses BreakdownBeta
How Cerevel Therapeutics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -433 | 113 | 335 |
| 30 Sep 23 | 0 | -393 | 96 | 319 |
| 30 Jun 23 | 0 | -397 | 94 | 305 |
| 31 Mar 23 | 0 | -388 | 91 | 303 |
| 31 Dec 22 | 0 | -352 | 88 | 280 |
| 30 Sep 22 | 0 | -318 | 78 | 247 |
| 30 Jun 22 | 0 | -280 | 69 | 216 |
| 31 Mar 22 | 0 | -243 | 61 | 180 |
| 31 Dec 21 | 0 | -225 | 58 | 162 |
| 30 Sep 21 | 0 | -196 | 45 | 144 |
| 30 Jun 21 | 0 | -173 | 44 | 128 |
| 31 Mar 21 | 0 | -146 | 41 | 113 |
| 31 Dec 20 | 0 | -148 | 40 | 103 |
| 30 Sep 20 | 0 | -175 | 48 | 95 |
| 30 Jun 20 | 0 | -172 | 45 | 88 |
| 31 Mar 20 | 0 | -151 | 40 | 73 |
| 31 Dec 19 | 0 | -128 | 33 | 50 |
Quality Earnings: CERE is currently unprofitable.
Growing Profit Margin: CERE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CERE is unprofitable, and losses have increased over the past 5 years at a rate of 15.9% per year.
Accelerating Growth: Unable to compare CERE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CERE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: CERE has a negative Return on Equity (-64.24%), as it is currently unprofitable.